이리덱스IRIX 주가

♻️ 재탕[4] 내부자 거래 — 4

[4] 내부자 거래 — 4

Iridex Corp (NASDAQ:IRIX) Q1 Loss Narrower Than Expected, Glaucoma Portfolio Strengthens

Iridex Q1 2026 results showed a narrower-than-expected loss of $0.03/share, beating estimates. Revenue was $11.8M, slightly below forecasts, with strong glaucoma portfolio growth offsetting retina weakness. The company reaffirmed full-year guidance.

♻️ 재탕IRIDEX Corporation (IRIX) Q1 2026 Earnings Call Transcript

IRIDEX Corporation (IRIX) Q1 2026 Earnings Call May 19, 2026 5:00 PM EDTCompany ParticipantsPatrick Mercer - CEO, President & DirectorRomeo Dizon -...

Iridex Q1 2026 Earnings Call: Complete Transcript

Iridex Affirms FY2026 Sales Guidance of $51.000M-$53.000M vs $53.227M Est

Iridex (NASDAQ:IRIX) affirms FY2026 sales outlook from $51.000 million-$53.000 million to $51.000 million-$53.000 million vs $53.227 million estimate.

Iridex Q1 EPS $(0.03) Beats $(0.07) Estimate, Sales $11.799M Miss $11.910M Estimate

Iridex (NASDAQ:IRIX) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.07) by 57.14 percent. This is a 70 percent increase over losses of $(0.10) per share from the same

Earnings Scheduled For May 19, 2026

[10-Q] 분기 실적 — 10-Q

[8-K] 중대 사건 — 8-K